How Can We Help?
Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[3][4] It targets the trabecular meshwork directly.[4]
References
- ^ "Search Page - Drug and Health Product Register". 23 October 2014.
- ^ "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Retrieved 7 June 2022.
- ^ "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension" (Press release). Valeant Pharmaceuticals International, Inc.
- ^ a b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
Recent Comments